Filing Flows › Ginkgo Bioworks Holdings (DNA) › Q1 2026
Ginkgo Bioworks Holdings (DNA) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Ginkgo Bioworks Holdings (DNA) reported revenue of $19.5M for the first quarter 2026 (Q1 2026), -49% from a year earlier and -42% from the quarter before. Operating margin was -366.5%, net loss $82.6M (424.1% of revenue).
Ginkgo Bioworks Holdings, Q1 2026: revenue $19.5M (-49% year over year), operating margin -366.5%, net loss $82.6M, operating cash flow −$46.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $19.5M | -42% | -49% |
| Operating profit | −$71.4M | — | — |
| Net earnings | −$82.6M | — | — |
| Operating cash flow | −$46.7M | — | — |
What changed
Revenue was $19.5M in Q1 2026, down 49% year over year and down 42% from the previous quarter.
Operating costs exceeded revenue by $71.4M, an operating margin of -366.5%. Total costs fell 24% while revenue fell 49%. The quarter ended with a net loss of $82.6M, wider than the previous quarter's $80.8M loss.
Operating cash flow was −$46.7M. Non-cash charges added back $12.8M of depreciation and amortization and $15.9M of share-based compensation. Working capital and other items added $7.2M. Capital expenditures of $1.9M exceeded it, leaving free cash flow of −$48.6M.
Questions
What was Ginkgo Bioworks Holdings' revenue in the first quarter 2026?
Ginkgo Bioworks Holdings (DNA) reported revenue of $19.5M for the first quarter 2026 (Q1 2026), -49% from a year earlier and -42% from the quarter before.
Was Ginkgo Bioworks Holdings profitable in the first quarter 2026?
Operating loss was $71.4M (-366.5% of revenue) and net loss $82.6M.